Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
Petvivo Holdings Inc (OTCQB: PETV)
MINNEAPOLIS, MN, U.S., June 2, 2021 /EINPresswire.com/ – PetVivo Holdings, Inc. (OTCQB: PETV) (the “Company”), an emerging biomedical device company with sales of US $ 18 billion in the veterinary market . USD announced today that it will be exhibiting at the Veterinary Meeting & Expo Conference June 5-9, 2021 at the Orange County Convention Center in Orlando, FL.
The company’s management is pleased to meet many of the 15,000+ attendees to unveil its flagship product, KUSH®, a veterinary injection of sterilized, naturally-derived hydrogel microparticles that are wet, slippery and spongy and used to treat lameness and other joint-related conditions such as osteoarthritis. VMX is the largest veterinary conference in the United States and is home to many of the best industry experts.
“We look forward to networking and building relationships with industry leaders who will help advance our first veterinary device for the treatment of osteoarthritis, KUSH,” said John Lai, chief executive officer of PetVivo Holdings, Inc.
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/
Conference details:
Veterinary Meeting & Expo (VMX) conference
Booth number: 1519
Events:
Sunday, June 6, 2021 9:00 a.m. – 5:30 p.m.
Monday, June 7, 2021 9:00 a.m. – 5:30 p.m.
Tuesday, June 8, 2021 9:00 a.m. – 5:30 p.m.
Wednesday, June 9, 2021 9:00 a.m. – 2:00 p.m.
Location: South Hall of the Orange County Convention Center
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on manufacturing, marketing, and licensing innovative pet medical devices and therapeutics. The company’s strategy is to use human therapies to treat pets in a capital and time efficient manner. A key part of this strategy is accelerating sales growth in veterinary products, which hit the market much earlier than more strictly regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and humans. A portfolio of eighteen patents protect the company’s biomaterials, products, production processes and application methods. The company’s flagship product, Kush, a veterinarian-administered intra-articular injection for the treatment of osteoarthritis in dogs and horses, is expected to go on sale later this year.
Forward-Looking Commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that are not solely based on historical or current facts, including, but not limited to, the company’s proposed development and commercial schedule, and which are made possible by the use of words such as “may,” “will,” ” expect “can be identified”, “project”, “estimate”, “anticipate”, “plan”, “believe”, “potentially”, “should”, “continue” or the negative versions of these words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the possible listing of the company’s common stock on the Nasdaq, are based on information currently available to the company and its current plans or expectations and are subject to a number of uncertainties and risks that could materially affect current plans. Risks relating to the company’s business are fully described in the company’s Annual Report on Form 10-K for the year ended March 31, 2020 and in other periodic and current reports filed with the Securities and Exchange Commission. The company undertakes no obligation to update or change its forward-looking statements as a result of new information, future events or for any other reason, and expressly disclaims this obligation.
John Lai
Petvivo Holdings, Inc.
+1 952-405-6216
email us here
You just read:
News provided by
June 02, 2021, 12:00 GMT
EIN Presswire’s priority is source transparency. We don’t allow opaque clients, and our editors try to carefully weed out false and misleading content. If, as a user, you see something that we have overlooked, please make us aware of it. Your help is welcome. ONE Presswire, Everyone’s Internet News Presswire ™, seeks to define some of the boundaries that are appropriate in the world today. Please see our editorial guidelines for more information.
Submit your press release
